Eur J Cancer. 2014 Dec;50(18):3161-7. doi: 10.1016/j.ejca.2014.10.006.
The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed.
Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed.
The estimated rate of no evidence of disease was 94.0% for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82% and 2.3%, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95% confidence interval (CI), 4.2–94.4, p < 0.001) and disease-related mortality (95% CI, 2.2–163.9, p = 0.007).
The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs.
博来霉素、依托泊苷和顺铂（BEP）联合治疗目前是最广泛用于治疗恶性卵巢生殖细胞肿瘤（MOGCT）的方法。本研究旨在评估台湾地区使用 3 天 BEP 方案治疗 MOGCT 的疗效和不良反应。同时分析 MOGCT 患者的预后因素。
从台湾妇科肿瘤学会数据库中确定了 239 例 MOGCT 患者，其中 204 例患者接受了术后 BEP 化疗，对这些患者进行了分析。
204 例接受辅助 BEP 方案的患者中，无疾病证据的估计率为 94.0%。在 853 个化疗周期中，共记录了 7 例 3/4 级血液学不良反应，包括 4 例中性粒细胞减少症，1 例全血细胞减少症，2 例中性粒细胞减少症发热。血液学和非血液学不良反应的发生率分别为 0.82%和 2.3%。无治疗相关死亡。在预后因素分析中，只有肿瘤分期对疾病复发（95%置信区间（CI），4.2-94.4，p<0.001）和疾病相关死亡率（95%CI，2.2-163.9，p=0.007）有显著影响。
目前的 3 天辅助 BEP 方案对 MOGCT 患者有效且安全。
